A Benchtop Closed-Loop System Controlled by a Bio-Inspired Silicon Implementation of the Pancreatic β Cell

Nick Oliver, M.R.C.P., Pantelis Georgiou, Ph.D., Desmond Johnston, F.R.C.P., FMedSci., and Christofer Toumazou, F.R.S.

Abstract

The normal pancreatic β -cell membrane depolarizes in response to increasing concentrations of glucose in a bursting pattern. At <7 mM (126 mg/dl), the cell is electrically silent. The bursting pulse width increases as glucose rises >7 mM (126 mg/dl) until a continuous train of bursting is seen at >25 mM (450 mg/dl). A bio-inspired silicon device has been developed using analogue electronics to implement membrane depolarization of the β cell. The device is ultralow powered, miniaturized (5 × 5 mm), and produces a bursting output identical to that characterized in electrophysiological studies.

Objective:

The goal of this study was to demonstrate the ability of silicon implementation of β -cell electrophysiology to respond to a simulated glucose input and to drive an infusion pump *in vitro*.

Method:

The silicon device response to a current source was recorded at varying simulated glucose concentrations. Subsequently, the bursting response to a changing analyte concentration measured by an amperometric enzyme electrode was converted to a voltage, driving a syringe pump loaded with a 50-ml syringe containing water.

Results:

Bursting responses are comparable to those recorded in electrophysiology. Silicon β -cell implementation bursts with a pulse width proportional to concentration and is able to drive an infusion pump.

Conclusion:

This is the first *in vitro* demonstration of closed loop insulin delivery utilizing miniaturized silicon implementation of β -cell physiology in analogue electronics.

J Diabetes Sci Technol 2009;3(6):1419-1424

Author Affiliation: Institute of Biomedical Engineering, Imperial College, London

Abbreviations: (ATP) adenosine triphosphate, (CMOS) complementary metal oxide semiconductor

Keywords: β cell, closed loop, type 1 diabetes

Corresponding Author: Nick Oliver, Clinical Research Fellow, Institute of Biomedical Engineering, Imperial College, London SW7 2AZ, UK; email address <u>nick.oliver@imperial.ac.uk</u>